AMGEN INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,548 ARS | -1.94% |
|
+9.10% | +34.45% |
| 22/05 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
| 22/05 | Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test | MT |
| Sales 2024 * | 33B 29,387B 2,742B | Sales 2025 * | 33.96B 30,242B 2,822B | Capitalization | 164B 1,46,098B 13,633B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.13B 3,680B 343B | Net income 2025 * | 6.52B 5,809B 542B | EV / Sales 2024 * | 6.45 x |
| Net Debt 2024 * | 48.72B 43,382B 4,048B | Net Debt 2025 * | 43.88B 39,074B 3,646B | EV / Sales 2025 * | 6.12 x |
| P/E ratio 2024 * |
38.6
x | P/E ratio 2025 * |
24.8
x | Employees | 26,700 |
| Yield 2024 * |
3.02% | Yield 2025 * |
3.27% | Free-Float | 99.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Amgen Inc.
More recommendations
More press releases
More news
| 1 day | -1.94% | ||
| 1 week | +9.10% | ||
| Current month | +25.52% | ||
| 1 month | +28.37% | ||
| 3 months | +19.48% | ||
| 6 months | +53.66% | ||
| Current year | +34.45% |
1 week
11 927.00
13 280.00
1 month
9 855.5013 280.00
Current year
9 151.0014 352.00
1 year
3 446.3314 352.00
3 years
1 280.1714 352.00
5 years
273.6714 352.00
10 years
60.0814 352.00
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 01/06/01 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 23/19/23 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 18/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 03/17/03 |
Ellen Kullman
BRD | Director/Board Member | 68 | 14/16/14 |
Robert Williams
BRD | Director/Board Member | 75 | 17/14/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/24/24 | 12,548 | -1.94% | 1,799 |
| 23/24/23 | 12,797 | -0.73% | 2,717 |
| 22/24/22 | 12,890 | +2.77% | 817 |
| 21/24/21 | 12,542 | +5.26% | 842 |
| 20/24/20 | 11,916 | +3.60% | 590 |
End-of-day quote Buenos Aires S.E., May 24, 2024
More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
31/05/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
305.8
USD
Average target price
316.3
USD
Spread / Average Target
+3.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.51% | 727B | |
| +32.76% | 599B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +16.00% | 243B | |
| +8.26% | 205B | |
| -5.81% | 203B | |
| +0.31% | 164B |
- Stock Market
- Equities
- AMGN Stock
- AMGN Stock
